Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02327078 : A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
PhasePhase 1/Phase 2
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Male or female subjects, age 18 years or older

- Subjects with histologically or cytologically confirmed NSCLC, MEL, CRC, SCCHN,
ovarian cancer, recurrent B cell NHL or HL, or glioblastoma

- Presence of measurable disease by RECIST v1.1 for solid tumors or Cheson criteria for
B cell NHL (including DLBCL) or HL. For subjects with glioblastoma, presence of
measurable disease is not required.

- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1

- Fresh baseline tumor biopsies (defined as a biopsy specimen taken since completion of
the most recent prior chemotherapy regimen) are required for all cohorts except

Exclusion Criteria:

- Laboratory and medical history parameters not within Protocol-defined range

- Currently pregnant or breastfeeding

- Subjects who have received prior immune checkpoint inhibitors or an IDO inhibitor
(except select Phase 2 cohorts evaluating I/O relapsed or I/O refractory MEL).
Subjects who have received experimental vaccines or other immune therapies should be
discussed with the medical monitor to confirm eligibility

- Untreated central nervous system (CNS) metastases or CNS metastases that have

- Subjects with any active or inactive autoimmune process

- Evidence of interstitial lung disease or active, noninfectious pneumonitis

- Subjects with any active or inactive autoimmune process

- Ocular MEL
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557